All exploitation rights obtained.
France and the United States.
“VALBIOTIS is a French Research & Development company committed to scientific innovation for preventing and combating metabolic diseases. Founded in 2014, VALBIOTIS has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of products designed to reduce the risk of major metabolic diseases, based on a multi-target approach by the use of plant-based ingredients.”
VALBIOTIS products are specifically designed to reduce the risk factors of certain metabolic diseases in order to delay their onset, or if possible, to prevent at-risk conditions from developing into a disease. Notably, these products are derived from food plants and plant extracts and are subject to rigorous clinical and scientific development. The plants, composed of various active molecules, are the inspiration for this global approach to disease that is based on pleiotropic mechanisms of action. The solutions currently available are not sufficient to stem this worldwide pandemic that is putting the lives of patients at risk as well as burdening healthcare systems. VALBIOTIS believes in a different approach, one that complements current recommendations (healthier food choices, physical activity and sport, etc.).
Metabolic diseases are complex and require a pleiotropic approach. By opting to exclusively use plants in its products, VALBIOTIS focuses its R&D on the multi-target, synergistic effects produced by various biomolecules from the plant totum. VALBIOTIS teams have extensive scientific, clinical and regulatory knowledge, as well as high-level expertise in:
To enhance its capacity for and speed of innovation and development:
Creation of the Company at La Rochelle.
Discovery of active ingredient, "TOTUM-63".
Initial public offering on the Stock Exchange on the Euronext Growth market.
Presentation of its Phase I/II clinical results for the active ingredient TOTUM-63, at the American Diabetes Association 77th Scientific Sessions in San Diego, (California, USA).
Internalization of a technical platform designed for Discovery and Preclinical Research, on its Riom site.
VALBIOTIS succeeds in the industrial production of VALEDIA® in collaboration with the Pierre Fabre group.
Positive results from the Phase IIA clinical study of VALEDIA®.